-
公开(公告)号：US20230008076A1
公开(公告)日：2023-01-12
申请号：US17663169
申请日：2022-05-12
申请人： BicycleTx Limited
IPC分类号： C07K14/00 , A61K38/12 , C07K7/08 , A61P35/00 , C07K7/50 , C07K7/06 , C07K14/705 , C07K14/715
摘要： The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
-
公开(公告)号：US20220402971A1
公开(公告)日：2022-12-22
申请号：US17815805
申请日：2022-07-28
发明人： James R. Heath
IPC分类号： C07K7/50
摘要： Disclosed are compounds, compositions, and methods involving cyclic peptides that can bind to KRAS (G12D) oncogenic protein. For example, disclosed are cyclic peptides that selectively bind KRAS (G12D) oncogenic protein. Also disclosed are methods of inhibiting KRAS (G12D) oncogenic protein in a cancer cell expressing KRAS (G12D) oncogenic protein. In some forms, the method comprises incubating the cancer cell with any one or more of the disclosed cyclic peptides. In some forms, the method comprises bringing into contact the cancer cell with any one or more of the disclosed cyclic peptides.
-
公开(公告)号：US11351222B2
公开(公告)日：2022-06-07
申请号：US16348706
申请日：2017-11-09
发明人： Dehua Pei , Ziqing Qian
摘要： Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
-
公开(公告)号：US20220056140A1
公开(公告)日：2022-02-24
申请号：US17466607
申请日：2021-09-03
申请人： Invectys SA
摘要： The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the α3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
-
公开(公告)号：US20210309748A1
公开(公告)日：2021-10-07
申请号：US17212165
申请日：2021-03-25
申请人： Invectys SA
摘要： The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the α3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
-
公开(公告)号：US10774323B2
公开(公告)日：2020-09-15
申请号：US15537910
申请日：2015-12-21
申请人： LanthioPep B.V.
摘要： The present invention relates to methods for displaying cyclic peptides on the surface of bacteriophage particles and collections thereof.
-
7.发明申请公开(公告)号：US20190282654A1
公开(公告)日：2019-09-19
申请号：US16348706
申请日：2017-11-09
发明人： Dehua PEI , Ziqing QIAN
摘要： Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
-
公开(公告)号：US10308683B2
公开(公告)日：2019-06-04
申请号：US15740822
申请日：2016-07-01
申请人： DEINOVE
发明人： Josef Aszodi , Denis Carniato , Dominique Le Beller , Guillaume Lesquame , Marie-Helene Quernin
摘要： The invention relates to a new bicyclic lipolantipeptide, representing a new class of lantipeptide, and salts thereof, their preparation from a culture of a Microbacterium arborescens, and their use as antimicrobial agent in the prevention and treatment of infections in humans, animals or plants.
-
公开(公告)号：US10300109B2
公开(公告)日：2019-05-28
申请号：US15349478
申请日：2016-11-11
发明人： Huw M. Nash , Rosana Kapeller-Libermann , Jia-Wen Han , Tomi K. Sawyer , Justin Noehre , Noriyuki Kawahata
摘要： Disclosed are peptidomimetic macrocycles comprising a helix, such as an alpha helix, and methods of using such macrocycles for the treatment of disease such as cancer. In other aspects, the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid, or may comprise a crosslinker linking the α-positions of at least two amino acids or at least one of said two amino acids may be an α,α-disubstituted amino acid. Further included is the targeting of components of the Wnt signaling pathway such as the Tcf4-/3-catenin complex.
-
10.发明申请公开(公告)号：US20180079782A1
公开(公告)日：2018-03-22
申请号：US15831087
申请日：2017-12-04
发明人： Ashok Bhandari , Gregory Bourne , Xiaoli Cheng , Brian Troy Frederick , Jie Zhang , Dinesh V. Patel , David Liu
摘要： The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease.
-
-
-
-
-
-
-
-
-
搜索结果
257 条记录 (耗时 0.033 秒)
